Written and maintained by CASRAI Editorial Board
Last updated
This page describes vaccine platforms and general laboratory and biotechnology practices; it is not individual medical advice.
Short answer
A protein subunit vaccine delivers isolated, purified pathogen proteins—such as viral surface spikes or bacterial toxoids—rather than whole live or inactivated pathogens. Produced primarily through recombinant expression systems and formulated with immunostimulatory adjuvants, these vaccines stimulate targeted antibody and cellular immune responses with high safety, low reactogenicity, and standard refrigerated (+2°C to +8°C) distribution stability.
Definition and scope
A protein subunit vaccine is an immunization platform based on isolated, non-infectious antigenic components of a pathogen. Unlike whole-pathogen vaccines that rely on attenuated or inactivated microbes, subunit formulations present only the specific epitopes required to train protective immunity. Modern platforms encompass recombinant monomeric proteins, multimeric complexes, virus-like particles (VLPs), and protein-polysaccharide conjugates.
Historically, early subunit preparations were isolated from pathogen cultures or biological fluids, such as plasma-derived hepatitis B surface antigens and acellular pertussis extracts. Contemporary biomanufacturing relies almost exclusively on recombinant DNA technology, cloning target sequences into heterologous expression vectors across mammalian, insect, or microbial host systems.
Unlike nucleic acid vaccines that deliver genetic instructions requiring host cells to perform synthetic mRNA capping and in vivo translation, protein subunit vaccines deliver pre-assembled, purified antigens directly. Regulatory oversight and quality standards are defined by World Health Organization (WHO) Technical Report Series No. 987, Annex 4, and corresponding FDA and EMA biologics frameworks.
How it works or how it is used in practice
Developing and deploying a protein subunit vaccine involves upstream genetic design, bioprocessing, downstream purification, and adjuvant formulation:
1. Antigen Engineering and Prefusion Stabilization
Vaccine design targets microbial surface proteins recognized by neutralizing antibodies. Because viral envelope glycoproteins often exist in metastable conformations that trigger fusion rearrangements, stabilizing the prefusion state is critical. Recombinant spike glycoproteins (such as SARS-CoV-2 spike in NVX-CoV2373) incorporate targeted proline substitutions (2P mutations) and furin cleavage site knockouts to preserve neutralizing epitopes.
2. Expression Platforms in Bioreactor Systems
Recombinant genes are cultured in scalable bioreactor systems under controlled dissolved oxygen, pH, and temperature. Host systems dictate post-translational modifications (PTMs):
- Chinese Hamster Ovary (CHO) cells: Deliver authentic human-like branched N-glycosylation and sialylation for complex glycoproteins like Varicella-Zoster Virus (VZV) glycoprotein E (gE) in Shingrix.
- Insect cells via BEVS: The Baculovirus Expression Vector System (BEVS) in Spodoptera frugiperda (Sf9) cells achieves high-density expression and self-assembly of multimeric nanoparticles without serum.
- Yeast cultures: Saccharomyces cerevisiae and Pichia pastoris provide cost-effective eukaryotic fermentation, established in recombinant Hepatitis B surface antigen (HBsAg) vaccines.
3. Downstream Purification and Quality Control
Harvested fluids undergo multi-stage downstream protein purification strategies, including affinity, ion-exchange, and size-exclusion chromatography (SEC). Under WHO TRS 987 guidelines, host-cell DNA must be cleared to ≤10 ng per dose, host-cell proteins (HCP) are strictly controlled to ppm levels, and nanofiltration validates viral clearance.
4. Adjuvant Formulation and Immune Priming
Because purified recombinant proteins lack pathogen-associated molecular patterns (PAMPs), they exhibit low intrinsic immunogenicity alone. Formulating with specialized vaccine adjuvants is mandatory to trigger pattern recognition receptors (PRRs):
- Aluminum salts (Alum): Form particulate depots and trigger the NLRP3 inflammasome, stimulating strong humoral titers.
- Liposomal TLR agonists (AS01B): Formulated with MPL (TLR4 agonist) and QS-21 saponin in liposomes, driving robust CD4+ Th1 cellular immunity.
- Saponin nanoparticles (Matrix-M): Saponin-phospholipid nanoparticles facilitate lymphatic drainage and accelerate antigen-presenting cell (APC) uptake.
Types or related concepts
The manufacturing characteristics and trade-offs of recombinant subunit vaccines depend on the chosen expression host platform:
| Expression Host | Post-Translational Modifications (PTMs) | Yield and Kinetics | Primary Downstream Challenge | Licensed Vaccine Examples |
|---|---|---|---|---|
| Mammalian (CHO) | Authentic complex human-like N- and O-glycans; terminal sialylation; correct chaperone folding | Moderate yield (1–5 g/L); slower doubling time (18–24 h) | High media costs; clearing host-cell proteins and adventitious retroviruses | Shingrix (VZV gE antigen in CHO; FDA BLA 125614) |
| Insect (BEVS / Sf9) | Simple paucimannose N-glycans; excellent multimeric assembly into nanoparticles and VLPs | High yield; rapid suspension growth (18–24 h doubling) | Clearing recombinant baculovirus vector; paucimannose glycan profiling | Novavax NVX-CoV2373 (SARS-CoV-2 spike in Sf9); Flublok (hemagglutinin) |
| Yeast (S. cerevisiae) | Core eukaryotic glycosylation; prone to high-mannose hyperglycosylation | Very high biomass; scalable low-cost fermentation | Hyperglycosylation can shield epitopes; requires glycoengineered strains | Engerix-B and Recombivax HB (HBsAg in yeast); Corbevax |
| Bacterial (E. coli) | No post-translational glycosylation; limited multi-domain disulfide pairing | Rapid doubling (20–30 min); lowest raw material cost | Insoluble inclusion bodies requiring refolding; high endotoxin (LPS) burden | Hecolin (Hepatitis E capsid in E. coli); bacterial toxoids |
Where it matters for labs, clinics or supply decisions
Deploying protein subunit vaccines involves operational trade-offs across cold-chain logistics, clinic handling, and release testing:
- Refrigerated cold chain (+2°C to +8°C): Subunit vaccines avoid the -70°C ultracold freezers required for mRNA vaccines, functioning within standard clinic refrigeration networks. However, formulations are freeze-sensitive; freezing disrupts aluminum and liposomal adjuvants, permanently inactivating the vaccine.
- Presentation formats: Formulations are supplied either as ready-to-use liquid suspensions (e.g., Novavax NVX-CoV2373) or two-vial kits requiring point-of-care reconstitution with liquid adjuvant (e.g., Shingrix). Reconstitution must use only the supplied adjuvant diluent.
- Clinical safety in vulnerable populations: Because subunit vaccines contain no replicating pathogens, they are well-tolerated in immunocompromised patients, older adults, and individuals where live vaccines are contraindicated.
- Bioanalytical release testing: Laboratory lot release relies on SEC-HPLC for monomer purity (>90–95%), surface plasmon resonance (SPR) or ELISA for functional epitope binding affinity, and LAL assays (USP <85>) to verify endotoxin clearance below pyrogenicity thresholds.
Common misunderstandings
- Misunderstanding: Subunit vaccines contain live virus.
Reality: Subunit vaccines contain only purified, non-infectious protein fragments produced in bioreactors. They contain zero genetic material needed for viral replication and cannot cause disease or revert to virulence. - Misunderstanding: Adjuvants are optional additives.
Reality: Isolated recombinant proteins lack the microbial danger signals (PAMPs) of whole pathogens. Administering pure soluble protein without an adjuvant triggers poor antibody response; adjuvants are essential to activate innate pattern recognition receptors. - Misunderstanding: All host systems produce identical proteins.
Reality: Hosts differ in post-translational modifications. Bacterial systems lack glycosylation, yeast attaches high-mannose chains, insect cells add paucimannose, and CHO cells provide complex branched sialylated glycans, directly affecting antigen folding and epitope exposure. - Misunderstanding: Subunit vaccines require ultra-cold freezers.
Reality: Subunit vaccines are engineered for standard refrigeration (+2°C to +8°C) and must never be frozen.
FAQ from questions
What is the difference between a protein subunit vaccine and an mRNA vaccine?
A protein subunit vaccine delivers pre-manufactured, purified antigen proteins directly to the immune system alongside an adjuvant. An mRNA vaccine delivers synthetic genetic transcripts inside lipid nanoparticles, instructing host cells to synthesize the antigen internally before displaying it to immune cells.
Why do protein subunit vaccines require adjuvants?
Because purified recombinant antigens lack whole-pathogen microbial components (PAMPs), they do not naturally trigger innate danger sensors. Adjuvants supply the required innate immune activation, creating localized antigen depots and stimulating dendritic cells to drive protective antibody titers and long-term immunological memory.
Which expression platforms are used to produce protein subunit vaccines?
Commercial and clinical subunit vaccines utilize four main expression hosts: mammalian cells (e.g., CHO cells for Shingrix), insect cell-baculovirus systems (e.g., Sf9 cells for Novavax NVX-CoV2373), yeast cultures (S. cerevisiae for Hepatitis B), and bacterial fermentation (E. coli for non-glycosylated proteins and toxoids).
Can a protein subunit vaccine cause infection or transmit disease?
No. Protein subunit vaccines contain neither whole live viruses nor bacterial pathogens. Because they contain only isolated, purified protein components and no replicating genetic genome, they cannot cause infection or shed pathogen particles.
Sources
- World Health Organization (WHO). (2014). Guidelines on the quality, safety and efficacy of biotherapeutic protein products prepared by recombinant DNA technology. WHO Technical Report Series, No. 987, Annex 4. URL: https://www.who.int/publications/m/item/trs-987-annex-4 (Read November 9, 2026).
- World Health Organization (WHO). (2014). Good manufacturing practices for biological products. WHO Technical Report Series, No. 986, Annex 2. URL: https://www.who.int/publications/m/item/trs-986-annex-2 (Read November 9, 2026).
- U.S. Food and Drug Administration (FDA). (2021). Shingrix (Zoster Vaccine Recombinant, Adjuvanted) Prescribing Information. Reference ID: BLA 125614. URL: https://www.fda.gov/vaccines-blood-biologics/vaccines/shingrix (Read November 9, 2026).
- U.S. Food and Drug Administration (FDA). (2023). Novavax COVID-19 Vaccine, Adjuvanted Fact Sheet and Prescribing Information. URL: https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/novavax-covid-19-vaccine-adjuvanted (Read November 9, 2026).
- National Center for Biotechnology Information (NCBI). PubMed Central. Review of Recombinant Subunit Vaccine Platforms and Adjuvant Formulations. PMC9368541 / PMC8621455. URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9368541/ (Read November 9, 2026).
